These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15312851)

  • 1. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.
    Kipshidze N; Dangas G; Tsapenko M; Moses J; Leon MB; Kutryk M; Serruys P
    J Am Coll Cardiol; 2004 Aug; 44(4):733-9. PubMed ID: 15312851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary artery restenosis: a paradigm of current treatment approaches.
    Kiernan TJ; Kiernan GD; Yan BD
    Minerva Cardioangiol; 2009 Feb; 57(1):77-94. PubMed ID: 19202520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restenosis related to percutaneous coronary intervention has been solved?
    Kivelä A; Hartikainen J
    Ann Med; 2006; 38(3):173-87. PubMed ID: 16720432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in researches of in-vivo re-endothelialization at the site of implanting cardiovascular devices].
    Chen J; Li Q; Chen J; Huang N
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Dec; 26(6):1380-3. PubMed ID: 20095508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vessel wall reaction in restenosis.
    Schwartz RS
    Semin Interv Cardiol; 1997 Jun; 2(2):83-8. PubMed ID: 9546996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying drug-eluting stents in clinical practice.
    King SB
    Am J Cardiol; 2007 Sep; 100(5A):25K-31K. PubMed ID: 17719350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization.
    Liuzzo JP; Ambrose JA; Coppola JT
    J Invasive Cardiol; 2005 Sep; 17(9):497-502. PubMed ID: 16145242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing restenosis after coronary angioplasty.
    Popma JJ; Topol EJ
    Am J Med; 1990 Jan; 88(1N):16N-24N. PubMed ID: 2195881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation and restenosis after percutaneous coronary interventions.
    Toutouzas K; Colombo A; Stefanadis C
    Eur Heart J; 2004 Oct; 25(19):1679-87. PubMed ID: 15451145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery stents: Part I. Evolution of percutaneous coronary intervention.
    Newsome LT; Kutcher MA; Royster RL
    Anesth Analg; 2008 Aug; 107(2):552-69. PubMed ID: 18633035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention?
    Gidlöf AC; Ocaya P; Krivospitskaya O; Sirsjö A
    Clin Sci (Lond); 2008 Jan; 114(1):19-25. PubMed ID: 18047466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention.
    Noordeloos AM; Soullié T; Duckers HJ; Serruys PW
    Endothelium; 2006; 13(6):431-9. PubMed ID: 17169775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is inflammation a contributor for coronary stent restenosis?
    Li JJ; Nie SP; Zhang CY; Gao Z; Zheng X; Guo YL
    Med Hypotheses; 2007; 68(5):945-51. PubMed ID: 17045418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.
    Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A
    Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology and burden of restenosis.
    Weintraub WS
    Am J Cardiol; 2007 Sep; 100(5A):3K-9K. PubMed ID: 17719351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current drug-eluting stents in complex patients and lesions.
    Elezi S; Dibra A; Schömig A; Kastrati A
    Minerva Cardioangiol; 2006 Feb; 54(1):5-22. PubMed ID: 16467738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.
    Birkenhauer P; Yang Z; Gander B
    J Pharm Pharmacol; 2004 Nov; 56(11):1339-56. PubMed ID: 15525440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
    Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
    J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial cell migration onto metal stent surfaces under static and flow conditions.
    Sprague EA; Luo J; Palmaz JC
    J Long Term Eff Med Implants; 2000; 10(1-2):97-110. PubMed ID: 10947633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.